Do analysts prefer ATYR or COYA?

Coya Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 218.78%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Do analysts recommend OKUR or ATYR?

OnKure Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 583.59%. Given OnKure Therapeutics' higher probable upside, equities research analysts plainly believe OnKure Therapeutics is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is OKUR or ATYR more profitable?

OnKure Therapeutics' return on equity of -49.01% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% aTyr Pharma N/A -95.89% -69.67%

Do analysts rate CBUS or ATYR?

Cibus currently has a consensus price target of $9.00, suggesting a potential upside of 426.32%. Given Cibus' higher probable upside, research analysts clearly believe Cibus is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cibus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has better earnings & valuation, CBUS or ATYR?

aTyr Pharma has lower revenue, but higher earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cibus $3.64M 35.91 -$127.08M -$1.65 N/A aTyr Pharma $190K 148.27 -$74.12M -$0.62 N/A

Is CBUS or ATYR more profitable?

aTyr Pharma has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. aTyr Pharma's return on equity of -95.89% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,258.89% -287.03% -27.99% aTyr Pharma N/A -95.89% -69.67%

Do analysts recommend GNLX or ATYR?

Genelux presently has a consensus price target of $18.00, suggesting a potential upside of 603.13%. Given Genelux's stronger consensus rating and higher probable upside, equities research analysts clearly believe Genelux is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has higher earnings and valuation, GNLX or ATYR?

Genelux has higher earnings, but lower revenue than aTyr Pharma. Genelux is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 11,581.44 -$32.15M -$0.86 N/A aTyr Pharma $190K 148.27 -$74.12M -$0.62 N/A

Is GNLX or ATYR more profitable?

aTyr Pharma's return on equity of -95.89% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% aTyr Pharma N/A -95.89% -69.67%

Do analysts prefer BDTX or ATYR?

Black Diamond Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 442.33%. Given Black Diamond Therapeutics' higher probable upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is BDTX or ATYR more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% aTyr Pharma N/A -95.89% -69.67%

aTyr Pharma (ATYR) Competitors

$0.29 -0.01 (-2.35%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.29 +0.00 (+0.28%)

As of 10/2/2026 07:56 PM Eastern

Compare

ATYR vs. COYA, OKUR, CBUS, GNLX, and BDTX

Should you buy aTyr Pharma stock or one of its competitors? aTyr Pharma's main competitors and comparable companies include Coya Therapeutics (COYA), OnKure Therapeutics (OKUR), Cibus (CBUS), Genelux (GNLX), and Black Diamond Therapeutics (BDTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does aTyr Pharma compare to Coya Therapeutics?

aTyr Pharma (NASDAQ:ATYR) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

aTyr Pharma has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

aTyr Pharma has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

Coya Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 218.78%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Coya Therapeutics had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 1 mentions for Coya Therapeutics and 0 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.00 equaled Coya Therapeutics'average media sentiment score.

Company	Overall Sentiment
aTyr Pharma	Neutral
Coya Therapeutics	Neutral

Coya Therapeutics has higher revenue and earnings than aTyr Pharma. Coya Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	148.27	-$74.12M	-$0.62	N/A
Coya Therapeutics	$7.95M	14.19	-$21.23M	-$1.07	N/A

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 5.0% of aTyr Pharma shares are held by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Coya Therapeutics beats aTyr Pharma on 9 of the 16 factors compared between the two stocks.

How does aTyr Pharma compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by insiders. Comparatively, 5.0% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

OnKure Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 583.59%. Given OnKure Therapeutics' higher probable upside, equities research analysts plainly believe OnKure Therapeutics is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, OnKure Therapeutics had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 1 mentions for OnKure Therapeutics and 0 mentions for aTyr Pharma. OnKure Therapeutics' average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score.

Company	Overall Sentiment
OnKure Therapeutics	Neutral
aTyr Pharma	Neutral

OnKure Therapeutics' return on equity of -49.01% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
aTyr Pharma	N/A	-95.89%	-69.67%

OnKure Therapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

OnKure Therapeutics has higher earnings, but lower revenue than aTyr Pharma. OnKure Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
aTyr Pharma	$190K	148.27	-$74.12M	-$0.62	N/A

Summary

OnKure Therapeutics and aTyr Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does aTyr Pharma compare to Cibus?

Cibus (NASDAQ:CBUS) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Cibus had 5 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for Cibus and 0 mentions for aTyr Pharma. Cibus' average media sentiment score of 0.18 beat aTyr Pharma's score of 0.00 indicating that Cibus is being referred to more favorably in the media.

Company	Overall Sentiment
Cibus	Neutral
aTyr Pharma	Neutral

33.8% of Cibus shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 29.9% of Cibus shares are owned by company insiders. Comparatively, 5.0% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

aTyr Pharma has lower revenue, but higher earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	35.91	-$127.08M	-$1.65	N/A
aTyr Pharma	$190K	148.27	-$74.12M	-$0.62	N/A

aTyr Pharma has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. aTyr Pharma's return on equity of -95.89% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
aTyr Pharma	N/A	-95.89%	-69.67%

Cibus has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Cibus currently has a consensus price target of $9.00, suggesting a potential upside of 426.32%. Given Cibus' higher probable upside, research analysts clearly believe Cibus is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

aTyr Pharma beats Cibus on 9 of the 16 factors compared between the two stocks.

How does aTyr Pharma compare to Genelux?

Genelux (NASDAQ:GNLX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

37.3% of Genelux shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 5.0% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

aTyr Pharma's return on equity of -95.89% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
aTyr Pharma	N/A	-95.89%	-69.67%

Genelux presently has a consensus price target of $18.00, suggesting a potential upside of 603.13%. Given Genelux's stronger consensus rating and higher probable upside, equities research analysts clearly believe Genelux is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Genelux has higher earnings, but lower revenue than aTyr Pharma. Genelux is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	11,581.44	-$32.15M	-$0.86	N/A
aTyr Pharma	$190K	148.27	-$74.12M	-$0.62	N/A

Genelux has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

In the previous week, Genelux had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 1 mentions for Genelux and 0 mentions for aTyr Pharma. Genelux's average media sentiment score of 0.88 beat aTyr Pharma's score of 0.00 indicating that Genelux is being referred to more favorably in the media.

Company	Overall Sentiment
Genelux	Positive
aTyr Pharma	Neutral

Summary

Genelux beats aTyr Pharma on 8 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Black Diamond Therapeutics' average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score.

Company	Overall Sentiment
Black Diamond Therapeutics	Neutral
aTyr Pharma	Neutral

Black Diamond Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 442.33%. Given Black Diamond Therapeutics' higher probable upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Black Diamond Therapeutics has a beta of 3.32, suggesting that its stock price is 232% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 5.0% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Black Diamond Therapeutics' return on equity of -32.10% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
aTyr Pharma	N/A	-95.89%	-69.67%

Black Diamond Therapeutics has higher revenue and earnings than aTyr Pharma. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.55	$22.37M	-$0.75	N/A
aTyr Pharma	$190K	148.27	-$74.12M	-$0.62	N/A

Summary

Black Diamond Therapeutics beats aTyr Pharma on 9 of the 14 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATYR vs. The Competition

Export

Metric	aTyr Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.17M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-0.46	13.00	274.71	26.04
Price / Sales	148.27	1,288.64	656.46	105.13
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.42	16.57	10.93	6.31
Net Income	-$74.12M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-5.84%	-2.97%	-2.00%	-1.66%
1 Month Performance	-42.25%	-10.82%	-6.19%	-4.68%
1 Year Performance	-62.95%	19.00%	8.03%	1.57%

aTyr Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATYR aTyr Pharma	0.6935 of 5 stars	$0.29 -2.3%	N/A	-63.0%	$28.17M	$190K	N/A	58	Gap Down
COYA Coya Therapeutics	1.6152 of 5 stars	$4.98 -2.0%	$15.33 +207.9%	-21.1%	$119.17M	$7.95M	N/A	8
OKUR OnKure Therapeutics	2.3193 of 5 stars	$2.76 -4.8%	$17.50 +534.1%	-5.5%	$117.15M	N/A	N/A	45	High Trading Volume
CBUS Cibus	1.8897 of 5 stars	$1.47 -3.3%	$9.00 +512.2%	+18.8%	$116.17M	$3.64M	N/A	118	News Coverage Analyst Upgrade
GNLX Genelux	2.2031 of 5 stars	$2.47 -0.4%	$18.00 +628.7%	-42.5%	$112.21M	$10K	N/A	26	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATYR) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

aTyr Pharma (ATYR) Competitors

ATYR vs. COYA, OKUR, CBUS, GNLX, and BDTX

How does aTyr Pharma compare to Coya Therapeutics?

Summary

How does aTyr Pharma compare to OnKure Therapeutics?

Summary

How does aTyr Pharma compare to Cibus?

Summary

How does aTyr Pharma compare to Genelux?

Summary

How does aTyr Pharma compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

aTyr Pharma (ATYR) Competitors

ATYR vs. COYA, OKUR, CBUS, GNLX, and BDTX

How does aTyr Pharma compare to Coya Therapeutics?

Which has more volatility and risk, ATYR or COYA?

Is ATYR or COYA more profitable?

Do analysts prefer ATYR or COYA?

Does the media refer more to ATYR or COYA?

Which has preferable valuation and earnings, ATYR or COYA?

Do insiders and institutionals hold more shares of ATYR or COYA?

Summary

How does aTyr Pharma compare to OnKure Therapeutics?

Do institutionals & insiders believe in OKUR or ATYR?

Do analysts recommend OKUR or ATYR?

Does the media prefer OKUR or ATYR?

Is OKUR or ATYR more profitable?

Which has more volatility and risk, OKUR or ATYR?

Which has better earnings and valuation, OKUR or ATYR?

Summary

How does aTyr Pharma compare to Cibus?

Does the media prefer CBUS or ATYR?

Do institutionals & insiders hold more shares of CBUS or ATYR?

Which has better earnings & valuation, CBUS or ATYR?

Is CBUS or ATYR more profitable?

Which has more volatility & risk, CBUS or ATYR?

Do analysts rate CBUS or ATYR?

Summary

How does aTyr Pharma compare to Genelux?

Do institutionals and insiders have more ownership in GNLX or ATYR?

Is GNLX or ATYR more profitable?

Do analysts recommend GNLX or ATYR?

Which has higher earnings and valuation, GNLX or ATYR?

Which has more risk and volatility, GNLX or ATYR?

Does the media prefer GNLX or ATYR?

Summary

How does aTyr Pharma compare to Black Diamond Therapeutics?

Does the media refer more to BDTX or ATYR?

Do analysts prefer BDTX or ATYR?

Which has more volatility & risk, BDTX or ATYR?

Do institutionals & insiders have more ownership in BDTX or ATYR?

Is BDTX or ATYR more profitable?

Which has higher valuation & earnings, BDTX or ATYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools